Gedea Biotech

Gedea Biotech is a company that aims to make a sustainable contribution to global women’s health and limit the unnecessary use of antibiotics. They develop safe and effective treatments for vaginal infections and their complications. With a multidisciplinary team from Lund University, Gedea Biotech has developed pHyph, an antibiotic-free vaginal tablet that both treats and prevents bacterial vaginosis. In clinical trials, pHyph has shown excellent medical effects, with a symptom reduction in 90% of patients and a lower recurrence rate compared to antibiotic treatments. The company has been granted patents for pHyph formulation and obtained ISO13485 certification. Gedea Biotech has received funding from the European Union’s Horizon 2020 research and innovation program.